Interaction Checker

Interacciones de Ubrogepant

Ubrogepant (Ubrelvy) tiene 80 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 65; moderadas: 8; leves: 7; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (65)

  • AmiodaronaantiarrítmicoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Aprepitantinhibidor de CYP3A4Grave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Armodafiniloestimulante del SNCGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • AtazanavirantirretroviralGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Bosentáninductor de CYP3A4Grave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • CiclosporinainmunosupresorGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Cimetidinaantagonista H2Grave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Claritromicinaantibiótico macrólidoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • ClobazambenzodiazepinaGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • DarunavirantirretroviralGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Darunavir y cobicistatantirretroviralGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Deferasiroxsuplemento de hierroGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • DexametasonacorticosteroideGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • DronedaronaantiarrítmicoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • EfavirenzantirretroviralGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Efavirenz, lamivudina y tenofovirantirretroviralGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Eritromicinaantibiótico macrólidoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • EslicarbazepinaanticonvulsivoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • EtravirinaantirretroviralGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • EverolimusinmunosupresorGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • FenitoínaanticonvulsivoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Fluconazolantifúngico azólicoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • FosamprenavirantirretroviralGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Fosaprepitantinhibidor de CYP3A4Grave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • FosfenitoínaanticonvulsivoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • GriseofulvinaantifúngicoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Imatinibinhibidor de CYP3A4Grave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • IsoniazidaantibióticoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Itraconazolantifúngico azólicoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Ivacaftorinhibidor de CYP3A4Grave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Ketoconazolantifúngico azólicoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • LenacapavirantirretroviralGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Lopinavir y ritonavirantirretroviralGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Lorlatinibinductor de CYP3A4Grave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Mifepristonainhibidor de CYP3A4Grave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Mirabegrónagonista beta-adrenérgicoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Mitapivatinductor de CYP3A4Grave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Grave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Nafcilinaantibiótico del grupo de las penicilinasGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • NefazodonaantidepresivoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • NevirapinaantirretroviralGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • OxcarbazepinaanticonvulsivoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Grave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • PerampanelanticonvulsivoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Posaconazolantifúngico azólicoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • PrimidonaanticonvulsivoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Ranolazinafármaco que prolonga el intervalo QTGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • RifabutinaantibióticoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • RifampicinaantibióticoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • RifapentinaantibióticoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • RitonavirantirretroviralGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Suvorexantsedante-hipnóticoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Suzetriginainductor de CYP3A4Grave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Ticagrelorantiagregante plaquetarioGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • TopiramatoanticonvulsivoGrave

    Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

  • Voriconazolantifúngico azólicoGrave

    UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (etiqueta de Ubrogepant, Contraindicaciones)

Interacciones moderadas (8)

  • CarvedilolbetabloqueanteModerada

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • CiprofloxacinofluoroquinolonaModerada

    Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )] . (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Cúrcuma (curcumina)Plantas medicinales y suplementosModerada

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Dextrometorfano y quinidinafármaco serotoninérgicoModerada

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Eltrombopaginhibidor de OATP1B1Moderada

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • FluvoxaminaISRSModerada

    Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )] . (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Pomelo (toronja)Alimentos y bebidasModerada

    Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )] . (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • QuinidinaantiarrítmicoModerada

    Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (etiqueta de Ubrogepant, Interacciones medicamentosas)

Menciones leves (7)

  • Butalbital y paracetamolbarbitúricoLeve

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Butalbital, ácido acetilsalicílico y cafeínabarbitúricoLeve

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Butalbital, ácido acetilsalicílico, cafeína y codeínabarbitúricoLeve

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Butalbital, paracetamol y cafeínabarbitúricoLeve

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Butalbital, paracetamol, cafeína y codeínabarbitúricoLeve

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • Fenobarbital, hiosciamina, atropina y escopolaminabarbitúricoLeve

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (etiqueta de Ubrogepant, Interacciones medicamentosas)

  • MetohexitalbarbitúricoLeve

    In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (etiqueta de Ubrogepant, Interacciones medicamentosas)

Compruebe Ubrogepant frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.